Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 385-374-1724
clinicaltrials@recursionpharma.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Back

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Recruiting

Open to: ALL

Age: 18.0 - N/A

Manchester Oxford Glasgow London Newcastle upon Tyne

Medical Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)
Pancreatic Adenocarcinoma
Non-small Cell Lung Cancer (NSCLC)
Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
Triple Negative Breast Cancer (TNBC)

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2023 Jan 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered as specified in the treatment arm.

Intervention Arm Group : Phase 1: Dose Escalation Combination Therapy;Phase 1: Dose Escalation Monotherapy;Phase 2: Dose Expansion Combination Therapy;Phase 2: Dose Expansion Monotherapy;

Intervention Type : DRUG
Intervention Description : Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.

Intervention Arm Group : Phase 1: Dose Escalation Combination Therapy;Phase 2: Dose Expansion Combination Therapy;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Christie NHS Foundation Trust
    Manchester
  • Oxford University Hospitals NHS Foundation Trust
    Oxford
  • The Beatson West of Scotland Cancer Centre
    Glasgow
  • UCL Hospitals NHS Foundation Trust
    London
  • Newcastle Upon Tyne NHS Foundation Trust
    Newcastle upon Tyne

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 385-374-1724
clinicaltrials@recursionpharma.com



The study is sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05985655
Last updated 22 April 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top